The Cunniff lab is interested in how mitochondrial dynamics influence cell processes and is identifying new therapeutics targets for aggressive cancers.
Congratulations to Dr. Nate Shannon on his recently published manuscript! Lots of exciting findings to follow up on related to Miro1 and mitochondrial positioning. https://t.co/IbLRe7J4go
Come check out PhD candidate Victoria Gibson discuss the importance of Peroxiredoxin 3 in mesothelioma tumors at #SfRBM2024. SYMPOSIA SESSION 3: Unveiling the Therapeutic Potential: Exploring Redox Signaling from Fundamentals to Drug Targets 2:45pm @RedoxVT@RSOncologyLLC@SFRBM
PhD Candidate Nate Shannon's first author paper out as a pre-print. Very proud of Nate! Some very interesting DEGs dependent on Miro1 expression and an interesting and evolving cell cycle/ERK1/2 story! @UVMcancercenter@RedoxVT#mitochondria
https://t.co/aGTgTcdMfN
Excited to see Dean present exciting data around the Phase 1 trial of RSO-021 at #ASCO24. A redox-dependent cancer therapy currently being tested in Phase 2! @RedoxVT@UVMcancercenter@dean_fennell@RSOncologyLLC https://t.co/g0VCHRWvGl
#ASCO24 Abstracts have been published! See the short list of rapid oral abstracts in Developmental Therapeutics - Molecularly Targeted Agents & Tumor Biology and you will see our first-in-human phase 1 for RSO-021 @dean_fennell@CunniffLab @PRCLeicester
https://t.co/4MkeTGXoSi
Congratulations @dean_fennell, very much deserved. You lead a great team, it’s a privilege to be part of it and a pleasure working alongside you.
https://t.co/jo0oY3u8Qm
Sharing our 🔬scientific findings and preclinical data🫁. If you are at #AACR24#SanDiego stop by today to see our presentation ~ @9am_today Titled: First-in-class peroxiredoxin 3 (PRX3) inhibitor RSO-021 triggers mesenchymal-to-epithelial transition in #meso. #taketwo
Presenting two posters with new discoveries 🔬and potential biomarkers associated with RSO-021 anticancer activity @AACR San Diego, April 7th and April 9th. George Naumov will be there along with Brian Cunniff @CunniffLab, will you? #biotech#CancerResearch
Looking forward to presenting our new data in support of the anti-cancer activity of RSO-021, lots of fresh discoveries! @RedoxVT@dean_fennell@UVMcancercenter
Happy to announce our abstract has been approved 👏👏 #BTOG24 Our CSO Brian Cunniff, Phd, @CunniffLab will be presenting "First-in-class peroxiredoxin 3 (PRX3) inhibitors" poster. Stop by the welcome reception Wednesday April 17th, 18:30 – 20:00, say hello or ask questions.